Project Grant HT94252410001
Award Date
9/1/24
Completion Date
1/31/27
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Norfolk, VA 23508, USA
Similar Awards
The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
This federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) provides $961,900.00 to Virginia Commonwealth University (VCU) for the Early Detection of Cancer Disparity and Treatment Resistance in TNBC project. The 3-year award, effective February 1, 2024, supports research to advance early detection and treatment of triple-negative breast cancer (TNBC), which disproportionately impacts minority populations. The funding will enable...
This $1,535,039 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development Program (CFDA 12.420) supports research conducted by Wake Forest University Health Sciences (WFUHS) to study how the breast tissue microbiota regulates immune checkpoint blockade therapy responsiveness in triple-negative breast cancer. The research aims to advance scientific understanding and develop new treatment approaches for this aggressive form of breast cancer that...
This Project Grant award of $1,401,794.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Oregon Health & Science University (OHSU). The funding will support a 3-year research project investigating the impact of recent childbirth on breast cancer prognosis and tumor molecular phenotypes among young Black and White women. The research aims to enhance understanding of breast cancer disease progression and outcomes in this...
This $2,542,500.00 federal Project Grant award was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support research on therapeutic targeting of the tumor microenvironment in triple-negative breast cancer patients at high risk of relapse and preclinical models of lung metastases. The grant was awarded to Weill Medical College of Cornell University, a prominent academic medical institution, with a performance period from May 15, 2025...
This federal Project Grant award of $400,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, with a performance period from October 1, 2024 to September 30, 2026. The award supports research by the University of Maryland, Baltimore to develop "drug conjugates of modified LGR4/5/6 ligands for cancer treatment." The university, as the prime awardee, has extensive expertise in biomedical research, clinical trials, and...
The Defense Health Agency awarded a $579,375 Project Grant to the University of Nebraska Medical Center through the Military Medical Research and Development program (CFDA 12.420) to support research targeting APE1 interaction with DNA G-quadruplex to prevent metastasis in triple-negative breast cancer. The three-year award beginning December 30, 2022 will fund research by the University of Nebraska Medical Center to investigate medical solutions for metastatic breast cancer through innovative...
This $5,540,949 federal Project Grant award was made by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports focused ultrasound interventions for noninvasive precision therapy in primary and metastatic breast cancers. The award was made to the Rector & Visitors of the University of Virginia (UVA), who will serve as the prime recipient and perform the research over a 4-year period from September 2025 to September 2029. The...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,128,000 Project Grant to The Institute For Cancer Research to conduct research on "Restoring PALB2 Function as a Mechanism of PARP1 Resistance in BRCA1-Mutant EOC". The award, with a performance period from July 1, 2024 to June 30, 2028, supports innovative scientific research aimed at improving health outcomes for military service members, veterans, and the broader...